Sanctuary Advisors LLC Makes New $1.53 Million Investment in Halozyme Therapeutics, Inc. $HALO

Sanctuary Advisors LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, Holdings Channel.com reports. The firm acquired 19,611 shares of the biopharmaceutical company’s stock, valued at approximately $1,535,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership raised its stake in Halozyme Therapeutics by 29.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after buying an additional 749,484 shares in the last quarter. William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $196,540,000. Dimensional Fund Advisors LP boosted its position in shares of Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after acquiring an additional 25,731 shares in the last quarter. Norges Bank purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $128,201,000. Finally, Federated Hermes Inc. increased its holdings in shares of Halozyme Therapeutics by 8.5% in the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock valued at $105,972,000 after acquiring an additional 123,917 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Citizens Jmp raised their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Finally, HC Wainwright upped their target price on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,103 shares of company stock worth $5,226,496 in the last 90 days. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Trading Down 2.1%

HALO opened at $107.06 on Thursday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $109.66. The business’s 50 day moving average is $85.50 and its two-hundred day moving average is $74.39. The firm has a market cap of $12.15 billion, a price-to-earnings ratio of 31.96, a price-to-earnings-growth ratio of 0.44 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company’s revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, research analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.